ERA-话题@MedSci

#ERA#

425篇内容 | 3166人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1738999, encodeId=53b91e389993f, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, objectTitle=Theranexus宣布1b期研究结果，证明与多奈哌齐相比，其阿尔茨海默氏病候选药物THN201的药理学特性得到了扩展, objectType=article, longId=186520, objectId=88ea186520c4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=88ea186520c4, replyNumber=0, likeNumber=101, createdTime=2020-12-21, rootId=0, userName=124988c7m106暂无昵称, userId=e36234488643, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=88ea186520c4, moduleTitle=Theranexus宣布1b期研究结果，证明与多奈哌齐相比，其阿尔茨海默氏病候选药物THN201的药理学特性得到了扩展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=88ea186520c4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1739015, encodeId=ead41e3901591, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, objectTitle=Ann Rheum Dis：狼疮肾炎1年时缺乏EULAR/ERA-EDTA应答可以预测长期肾脏预后不良, objectType=article, longId=195482, objectId=495c19548214, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=495c19548214, replyNumber=0, likeNumber=73, createdTime=2020-10-06, rootId=0, userName=124988c7m106暂无昵称, userId=e36234488643, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=495c19548214, moduleTitle=Ann Rheum Dis：狼疮肾炎1年时缺乏EULAR/ERA-EDTA应答可以预测长期肾脏预后不良, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=495c19548214)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738997, encodeId=b7881e3899764, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, objectTitle=ADC Therapeutics针对CD19的抗体偶联药物loncastuximab tesirine，在弥漫性大B细胞淋巴瘤的II期临床中大获成功, objectType=article, longId=186029, objectId=4575186029eb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4575186029eb, replyNumber=0, likeNumber=84, createdTime=2020-11-03, rootId=0, userName=124988c7m106暂无昵称, userId=e36234488643, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4575186029eb, moduleTitle=ADC Therapeutics针对CD19的抗体偶联药物loncastuximab tesirine，在弥漫性大B细胞淋巴瘤的II期临床中大获成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4575186029eb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738974, encodeId=5f201e389748f, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, objectTitle=Alimen Pharm Therap ：无关饮食，肥胖还与不良排便习惯密切相关, objectType=article, longId=179989, objectId=a83f1e998909, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a83f1e998909, replyNumber=0, likeNumber=61, createdTime=2020-02-16, rootId=0, userName=124988c7m106暂无昵称, userId=e36234488643, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a83f1e998909, moduleTitle=Alimen Pharm Therap ：无关饮食，肥胖还与不良排便习惯密切相关, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a83f1e998909)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1739001, encodeId=5fd61e3900129, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, objectTitle=KSQ Therapeutics发现潜在活性优于PD-1的基因靶标，可用于开发针对性的工程化肿瘤浸润淋巴细胞（eTIL）治疗难治性实体瘤, objectType=article, longId=187862, objectId=f68418e862d3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f68418e862d3, replyNumber=0, likeNumber=74, createdTime=2020-08-10, rootId=0, userName=124988c7m106暂无昵称, userId=e36234488643, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f68418e862d3, moduleTitle=KSQ Therapeutics发现潜在活性优于PD-1的基因靶标，可用于开发针对性的工程化肿瘤浸润淋巴细胞（eTIL）治疗难治性实体瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f68418e862d3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1739004, encodeId=a18f1e390047e, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, objectTitle=JAMA Surg：促进术后恢复学会（ERA）护理方案与关节置换患者预后, objectType=article, longId=188307, objectId=75c718830e68, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=75c718830e68, replyNumber=0, likeNumber=62, createdTime=2020-10-05, rootId=0, userName=124988c7m106暂无昵称, userId=e36234488643, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=75c718830e68, moduleTitle=JAMA Surg：促进术后恢复学会（ERA）护理方案与关节置换患者预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=75c718830e68)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1739018, encodeId=6de01e39018ca, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, objectTitle=宣武医院多团队“联手”开展术后加速康复（ERAS）项目, objectType=article, longId=196182, objectId=0cf219618260, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0cf219618260, replyNumber=0, likeNumber=68, createdTime=2021-05-13, rootId=0, userName=124988c7m106暂无昵称, userId=e36234488643, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0cf219618260, moduleTitle=宣武医院多团队“联手”开展术后加速康复（ERAS）项目, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0cf219618260)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738977, encodeId=3e111e3897772, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, objectTitle=Cancer Gene Therapy：CRHBP能够抑制肾细胞肿瘤的恶化, objectType=article, longId=181690, objectId=4afd1816909b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4afd1816909b, replyNumber=0, likeNumber=68, createdTime=2019-11-15, rootId=0, userName=124988c7m106暂无昵称, userId=e36234488643, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4afd1816909b, moduleTitle=Cancer Gene Therapy：CRHBP能够抑制肾细胞肿瘤的恶化, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4afd1816909b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738980, encodeId=ac401e389805a, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, objectTitle=2019 ESPN/ERA-EDTA立场声明：西那卡塞在儿童透析中的应用, objectType=article, longId=182075, objectId=40a51820e56b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=40a51820e56b, replyNumber=0, likeNumber=12, createdTime=2020-04-28, rootId=0, userName=124988c7m106暂无昵称, userId=e36234488643, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=40a51820e56b, moduleTitle=2019 ESPN/ERA-EDTA立场声明：西那卡塞在儿童透析中的应用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=40a51820e56b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1739013, encodeId=ce4e1e390130f, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, objectTitle=Pharmacotherapy：塞来昔布治疗骨关节炎患者健康相关生活质量的功能状态评估, objectType=article, longId=193987, objectId=7fac19398e67, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7fac19398e67, replyNumber=0, likeNumber=69, createdTime=2021-02-03, rootId=0, userName=124988c7m106暂无昵称, userId=e36234488643, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7fac19398e67, moduleTitle=Pharmacotherapy：塞来昔布治疗骨关节炎患者健康相关生活质量的功能状态评估, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7fac19398e67)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738984, encodeId=bd251e389844c, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, objectTitle=Bigtera（大兆）助力生物医学大数据管理与分析, objectType=article, longId=183214, objectId=59ea18321490, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=59ea18321490, replyNumber=0, likeNumber=72, createdTime=2020-07-20, rootId=0, userName=124988c7m106暂无昵称, userId=e36234488643, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=59ea18321490, moduleTitle=Bigtera（大兆）助力生物医学大数据管理与分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=59ea18321490)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738988, encodeId=74331e3898829, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, objectTitle=.Interact Cardiovasc Thorac Surg：在右室缺血再灌注中七氟醚比异丙酚提供更好的血流动力学稳定性, objectType=article, longId=183890, objectId=6402183890df, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6402183890df, replyNumber=0, likeNumber=72, createdTime=2019-12-21, rootId=0, userName=124988c7m106暂无昵称, userId=e36234488643, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6402183890df, moduleTitle=.Interact Cardiovasc Thorac Surg：在右室缺血再灌注中七氟醚比异丙酚提供更好的血流动力学稳定性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6402183890df)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738998, encodeId=c1e61e38998b6, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, objectTitle=中山六院：ERAS给医疗带来的想象空间你或许想象不到, objectType=article, longId=186436, objectId=9aa21864360a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9aa21864360a, replyNumber=0, likeNumber=53, createdTime=2020-09-06, rootId=0, userName=124988c7m106暂无昵称, userId=e36234488643, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9aa21864360a, moduleTitle=中山六院：ERAS给医疗带来的想象空间你或许想象不到, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9aa21864360a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738973, encodeId=bfad1e3897364, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, objectTitle=Immunotherapy：益生菌提取物的鼻腔滴注能够抑制试验过敏性鼻炎, objectType=article, longId=179959, objectId=fc5f1e995961, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fc5f1e995961, replyNumber=0, likeNumber=70, createdTime=2019-10-13, rootId=0, userName=124988c7m106暂无昵称, userId=e36234488643, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fc5f1e995961, moduleTitle=Immunotherapy：益生菌提取物的鼻腔滴注能够抑制试验过敏性鼻炎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fc5f1e995961)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738970, encodeId=2eca1e38970a8, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, objectTitle=Gyroscope Theraputics获得5040万英镑的B轮融资，继续推进基因疗法治疗干性年龄相关性黄斑变性, objectType=article, longId=178780, objectId=f3c01e8780a4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f3c01e8780a4, replyNumber=0, likeNumber=52, createdTime=2019-11-01, rootId=0, userName=124988c7m106暂无昵称, userId=e36234488643, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f3c01e8780a4, moduleTitle=Gyroscope Theraputics获得5040万英镑的B轮融资，继续推进基因疗法治疗干性年龄相关性黄斑变性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f3c01e8780a4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1739003, encodeId=7aa61e39003b7, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, objectTitle=FDA批准了Agile Therapeutics每周一次的避孕贴片Twirla, objectType=article, longId=188270, objectId=e6841882e006, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e6841882e006, replyNumber=0, likeNumber=72, createdTime=2020-05-13, rootId=0, userName=124988c7m106暂无昵称, userId=e36234488643, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e6841882e006, moduleTitle=FDA批准了Agile Therapeutics每周一次的避孕贴片Twirla, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e6841882e006)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738992, encodeId=82911e3899292, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, objectTitle=Iterum Therapeutics宣布完成口服Sulopenem治疗尿道感染的III期临床试验注册, objectType=article, longId=185461, objectId=e368185461fe, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e368185461fe, replyNumber=0, likeNumber=58, createdTime=2020-04-09, rootId=0, userName=124988c7m106暂无昵称, userId=e36234488643, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e368185461fe, moduleTitle=Iterum Therapeutics宣布完成口服Sulopenem治疗尿道感染的III期临床试验注册, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e368185461fe)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1739011, encodeId=55ac1e39011ea, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, objectTitle=Alimentary Pharmacology Therapeutics：幽门螺杆菌感染可降低食道和近端胃的腺癌发生率 , objectType=article, longId=191616, objectId=54c019161677, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=54c019161677, replyNumber=0, likeNumber=89, createdTime=2020-05-03, rootId=0, userName=124988c7m106暂无昵称, userId=e36234488643, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=54c019161677, moduleTitle=Alimentary Pharmacology Therapeutics：幽门螺杆菌感染可降低食道和近端胃的腺癌发生率 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=54c019161677)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738993, encodeId=39301e38993d8, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, objectTitle=Leap Therapeutics将DKK1单抗DKN-01亚洲开发权利许可给百济神州，用于与PD-1单抗联用, objectType=article, longId=185777, objectId=0711185e771a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0711185e771a, replyNumber=0, likeNumber=53, createdTime=2020-02-10, rootId=0, userName=124988c7m106暂无昵称, userId=e36234488643, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0711185e771a, moduleTitle=Leap Therapeutics将DKK1单抗DKN-01亚洲开发权利许可给百济神州，用于与PD-1单抗联用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0711185e771a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738959, encodeId=cc811e38959f8, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, objectTitle=2019 EHA：TG Therapeutics的抗CD47 / CD19双特异性抗体TG-1801临床前抗淋巴瘤作用显著, objectType=article, longId=168714, objectId=1c1a168e1418, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1c1a168e1418, replyNumber=0, likeNumber=93, createdTime=2019-10-29, rootId=0, userName=124988c7m106暂无昵称, userId=e36234488643, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1c1a168e1418, moduleTitle=2019 EHA：TG Therapeutics的抗CD47 / CD19双特异性抗体TG-1801临床前抗淋巴瘤作用显著, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1c1a168e1418)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

ERA

2020-05-29

124988c7m106暂无昵称 (审核中...)

前往app查看评论内容

#ERA#

Theranexus宣布1b期研究结果，证明与多奈哌齐相比，其阿尔茨海默氏病候选药物THN201的药理学特性得到了扩展

2020-12-21

124988c7m106暂无昵称 (审核中...)

前往app查看评论内容

#ERA#

Ann Rheum Dis：狼疮肾炎1年时缺乏EULAR/ERA-EDTA应答可以预测长期肾脏预后不良

2020-10-06

124988c7m106暂无昵称 (审核中...)

前往app查看评论内容

#ERA#

ADC Therapeutics针对CD19的抗体偶联药物loncastuximab tesirine，在弥漫性大B细胞淋巴瘤的II期临床中大获成功

2020-11-03

124988c7m106暂无昵称 (审核中...)

前往app查看评论内容

#ERA#

Alimen Pharm Therap ：无关饮食，肥胖还与不良排便习惯密切相关

2020-02-16

124988c7m106暂无昵称 (审核中...)

前往app查看评论内容

#ERA#

KSQ Therapeutics发现潜在活性优于PD-1的基因靶标，可用于开发针对性的工程化肿瘤浸润淋巴细胞（eTIL）治疗难治性实体瘤

2020-08-10

124988c7m106暂无昵称 (审核中...)

前往app查看评论内容

#ERA#

JAMA Surg：促进术后恢复学会（ERA）护理方案与关节置换患者预后

2020-10-05

124988c7m106暂无昵称 (审核中...)

前往app查看评论内容

#ERA#

宣武医院多团队“联手”开展术后加速康复（ERAS）项目

2021-05-13

124988c7m106暂无昵称 (审核中...)

前往app查看评论内容

#ERA#

Cancer Gene Therapy：CRHBP能够抑制肾细胞肿瘤的恶化

2019-11-15

124988c7m106暂无昵称 (审核中...)

前往app查看评论内容

#ERA#

2019 ESPN/ERA-EDTA立场声明：西那卡塞在儿童透析中的应用

2020-04-28

124988c7m106暂无昵称 (审核中...)

前往app查看评论内容

#ERA#

Pharmacotherapy：塞来昔布治疗骨关节炎患者健康相关生活质量的功能状态评估

2021-02-03

124988c7m106暂无昵称 (审核中...)

前往app查看评论内容

#ERA#

Bigtera（大兆）助力生物医学大数据管理与分析

2020-07-20

124988c7m106暂无昵称 (审核中...)

前往app查看评论内容

#ERA#

.Interact Cardiovasc Thorac Surg：在右室缺血再灌注中七氟醚比异丙酚提供更好的血流动力学稳定性

2019-12-21

124988c7m106暂无昵称 (审核中...)

前往app查看评论内容

#ERA#

中山六院：ERAS给医疗带来的想象空间你或许想象不到

2020-09-06

124988c7m106暂无昵称 (审核中...)

前往app查看评论内容

#ERA#

Immunotherapy：益生菌提取物的鼻腔滴注能够抑制试验过敏性鼻炎

2019-10-13

124988c7m106暂无昵称 (审核中...)

前往app查看评论内容

#ERA#

Gyroscope Theraputics获得5040万英镑的B轮融资，继续推进基因疗法治疗干性年龄相关性黄斑变性

2019-11-01

124988c7m106暂无昵称 (审核中...)

前往app查看评论内容

#ERA#

FDA批准了Agile Therapeutics每周一次的避孕贴片Twirla

2020-05-13

124988c7m106暂无昵称 (审核中...)

前往app查看评论内容

#ERA#

Iterum Therapeutics宣布完成口服Sulopenem治疗尿道感染的III期临床试验注册

2020-04-09

124988c7m106暂无昵称 (审核中...)

前往app查看评论内容

#ERA#

Alimentary Pharmacology Therapeutics：幽门螺杆菌感染可降低食道和近端胃的腺癌发生率

2020-05-03

124988c7m106暂无昵称 (审核中...)

前往app查看评论内容

#ERA#

Leap Therapeutics将DKK1单抗DKN-01亚洲开发权利许可给百济神州，用于与PD-1单抗联用

2020-02-10

124988c7m106暂无昵称 (审核中...)

前往app查看评论内容

#ERA#

2019 EHA：TG Therapeutics的抗CD47 / CD19双特异性抗体TG-1801临床前抗淋巴瘤作用显著

2019-10-29

科室
- - 订阅+
  - 更多科室
工具
服务